{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:48:09Z","timestamp":1765889289066,"version":"3.37.3"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"abstract":"<jats:p>Drug-induced subacute cutaneous lupus erythematosus (SCLE) is a lupus-like cutaneous eruption without systemic features caused by insult from a range of chemically diverse culprit drugs. In cases where remission is not achieved with drug discontinuation, treatment options generally involve those used to treat idiopathic SCLE, including topical or systemic corticosteroids, antimalarials or immunosuppressive drugs. We present a patient with drug-induced SCLE secondary to terbinafine with a prolonged course after drug cessation, who did not respond to classical treatments, but demonstrated rapid and sustained improvement within 48\u2005h of upadacitinib treatment.<\/jats:p>","DOI":"10.1093\/ced\/llae138","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T07:25:10Z","timestamp":1712906710000},"page":"1241-1243","source":"Crossref","is-referenced-by-count":3,"title":["A case of terbinafine-induced subacute cutaneous lupus erythematosus rapidly resolving with upadacitinib"],"prefix":"10.1093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1838-1123","authenticated-orcid":false,"given":"Tatiana","family":"Ninkov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sir Charles Gairdner Hospital , Nedlands, WA , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Von Nida","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sir Charles Gairdner Hospital , Nedlands, WA , Australia"},{"name":"Royal Street Dermatology , Yokine, WA , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"2024091818144890100_llae138-B1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/0961203309106176","article-title":"Drug-induced lupus: an update on its dermatologic aspects","volume":"18","author":"Marzano","year":"2009","journal-title":"Lupus"},{"key":"2024091818144890100_llae138-B2","doi-asserted-by":"crossref","first-page":"e001374","DOI":"10.1136\/rmdopen-2020-001374","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research","volume":"6","author":"Kerschbaumer","year":"2020","journal-title":"RMD Open"},{"key":"2024091818144890100_llae138-B3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3389\/fimmu.2020.00344","article-title":"Selective Janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions","volume":"11","author":"Fetter","year":"2020","journal-title":"Front Immunol"},{"key":"2024091818144890100_llae138-B4","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1111\/jdv.19604","article-title":"Efficacy of upadacitinib in a case of resistant lupus erythematosus tumidus","volume":"38","author":"Maione","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091818144890100_llae138-B5","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.2147\/CCID.S419344","article-title":"Treatment of discoid lupus erythematosus with upadacitinib: a case report","volume":"16","author":"Hu","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae138\/58341530\/llae138.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/10\/1241\/59183539\/llae138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/10\/1241\/59183539\/llae138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T18:14:52Z","timestamp":1726683292000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/10\/1241\/7645624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":5,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,4,15]]},"published-print":{"date-parts":[[2024,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae138","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,4,15]]}}}